KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Merck (MRK) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Merck (MRK) over the last 17 years, with Q3 2025 value amounting to $987.0 million.

  • Merck's Capital Expenditures rose 2605.36% to $987.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 billion, marking a year-over-year increase of 1728.97%. This contributed to the annual value of $3.4 billion for FY2024, which is 1271.03% down from last year.
  • Merck's Capital Expenditures amounted to $987.0 million in Q3 2025, which was up 2605.36% from $764.0 million recorded in Q2 2025.
  • Merck's 5-year Capital Expenditures high stood at $1.3 billion for Q1 2025, and its period low was $764.0 million during Q2 2025.
  • Its 5-year average for Capital Expenditures is $1.0 billion, with a median of $987.0 million in 2025.
  • As far as peak fluctuations go, Merck's Capital Expenditures skyrocketed by 7389.77% in 2021, and later plummeted by 1989.34% in 2023.
  • Over the past 5 years, Merck's Capital Expenditures (Quarter) stood at $1.2 billion in 2021, then dropped by 4.88% to $1.1 billion in 2022, then decreased by 13.93% to $989.0 million in 2023, then fell by 5.26% to $937.0 million in 2024, then rose by 5.34% to $987.0 million in 2025.
  • Its Capital Expenditures stands at $987.0 million for Q3 2025, versus $764.0 million for Q2 2025 and $1.3 billion for Q1 2025.